JLk, Global Experts Hold International Seminar... 'Doctor vs AI' Brain Disease Diagnosis Prediction Battle

Renowned professors considered global experts in stroke are visiting Korean AI medical solution company JLK to compete in stroke AI technology and prediction results, drawing significant public attention.

JLK (CEO Dongmin Kim), the first medical AI company to be listed, announced on the 25th that on the 11th of next month, internationally renowned stroke experts from multiple countries including the United States' Harvard and MD Anderson faculties, Japan, Taiwan, and the Philippines will visit JLK to hold an international stroke AI validation seminar (AI vs Human Experts competition for post-stroke END detection).

The global research team participating in the seminar consists of five members: John Wen-Yueh Chen from Harvard, Dawid Schellingerhout from MD Anderson, Manabu Inoue from Japan, Meng Lee from Taiwan, and Geraldine Siena L. Mariano from the Philippines.

These distinguished scholars in the field of stroke from various countries will each provide their clinical diagnosis based on MR images, then compare their accuracy rates with AI analysis results. According to officials, this competition will be used as evidence for JLK’s new solutions in the future. Additionally, in-depth discussions are planned regarding the diagnostic algorithms of JLK’s stroke AI solutions and strategies for overseas expansion.

JLK expects that the visit of these experts and the validation of its solutions will widely promote the company’s stroke AI diagnostic technology. Especially since globally renowned professors in the stroke field will diagnose the same images and directly compare their results with the AI’s analysis, it is anticipated that the superior technological capabilities of the solution will be demonstrated without reservation.

The researchers also foresee that this visit to JLK will provide an opportunity to personally experience the speed and accuracy of AI technology used in stroke diagnosis. Furthermore, as the elderly population increases worldwide, the incidence of stroke is also rising, leading to an expected increase in demand for stroke AI solutions that enable rapid diagnosis and treatment planning.

As JLK is currently focusing on overseas market entry in countries such as the United States and Japan, it plans to discuss tailored entry strategies with the researchers. In the U.S., JLK is concentrating on obtaining FDA approval and securing key hospitals to establish a stable supply base, while in Japan, it recently submitted PMDA approval applications for two solutions. The company will also exchange opinions with the researchers on obtaining health authority approvals and expanding supply chains in Southeast Asia and other Asian countries.

JLK CEO Dongmin Kim stated, "It is a special honor to host this event with leading global scholars in the stroke field. We expect that JLK, which has been steadily advancing with the goal of conquering stroke through artificial intelligence, and our stroke-specialized AI solutions will receive worldwide recognition for their technological excellence."

This content was produced with the assistance of AI translation services.